Amivantamab is a medication used in this trial to treat patients with a specific type of lung cancer. It works by targeting and blocking certain proteins on cancer cells, which can help slow down or stop the growth of the cancer.

Lazertinib is another medication included in the trial. It is designed to target and inhibit specific proteins that are involved in the growth and spread of cancer cells, particularly in patients who have a mutation in the EGFR gene.

Carboplatin is a type of chemotherapy used in the trial. It works by damaging the DNA of cancer cells, which prevents them from dividing and growing. This can help to shrink tumors and slow the progression of the disease.

Pemetrexed is also a chemotherapy drug used in the study. It interferes with the cancer cell’s ability to use folate, a vitamin that is necessary for cell division. By doing so, it can help to stop the growth of cancer cells.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer – This is a type of lung cancer that begins in the cells lining the lungs and is characterized by its spread beyond the original site. It is classified as “locally advanced” when it has spread to nearby tissues or lymph nodes but not to distant body parts. When it becomes “metastatic,” it means the cancer has spread to other organs or distant parts of the body. The disease often progresses through stages, starting from localized tumors to more widespread involvement. Symptoms may include persistent cough, chest pain, and difficulty breathing. The progression can vary, with some cases advancing more rapidly than others.